Abbott’s FreeStyle Libre® System & GLP-1 Meds Show Synergistic Impact in Type 2 Diabetes
ABBOTT PARK, Ill., March, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced new data…
The Future of Cardiac Care: Defying the Threat of Cardiovascular Disease
Cardiovascular disease (CVD) is the number 1 killer worldwide and claims millions…
